JOURNAL OF BUON, vol.16, no.1, pp.80-83, 2011 (SCI-Expanded)
Purpose: To retrospectively evaluate the efficacy and tolerability of mitomycin-C (MMC) in combination with fluoropyrimidines as salvage 3rd -or 4th-line therapy in metastatic colorectal cancer (MCRC) patients.